Lexicon Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mike Exton
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.9yrs |
| Board average tenure | 17.3yrs |
Recent management updates
Recent updates
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08CEO
Mike Exton (54 yo)
less than a year
Tenure
Dr. Michael Exton, also known as Mike, Ph D is CEO & Director of Lexicon Pharmaceuticals, Inc. from July 08, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP | 14.6yrs | US$1.42m | 0.049% $ 134.5k | |
| Executive Vice President of Innovation & Chemical Sciences | 23.4yrs | US$1.39m | 0.071% $ 193.8k | |
| Senior VP & Chief Medical Officer | 3.3yrs | US$1.53m | 0.013% $ 36.1k | |
| CEO & Director | less than a year | no data | no data | |
| Vice President of Finance & Accounting | 3.3yrs | no data | 0.013% $ 36.2k | |
| Vice President of Investor Relations & Corporate Communications | 1.1yrs | no data | no data | |
| Vice President of Compliance | 2.8yrs | no data | no data | |
| Vice President of Marketing | 1.5yrs | no data | no data | |
| Vice President of Sales & Training | no data | no data | no data | |
| Senior Vice President of Human Resources | 2.9yrs | no data | 0.015% $ 39.9k | |
| Senior Vice President of Regulatory & Quality Assurance | less than a year | no data | no data |
2.9yrs
Average Tenure
54yo
Average Age
Experienced Management: LXRX's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| Independent Chairman of the Board | 17.3yrs | US$127.82k | 0.37% $ 1.0m | |
| Independent Director | 24.8yrs | US$117.46k | 0.024% $ 66.4k | |
| Independent Director | 17.3yrs | US$100.52k | 0.069% $ 188.2k | |
| Independent Director | 17.3yrs | US$89.96k | 0.046% $ 126.6k | |
| Independent Director | 17.3yrs | US$104.96k | 0.013% $ 36.7k | |
| Chairman of Medical Advisory Board | 21.8yrs | US$82.87k | 0.011% $ 31.1k | |
| Independent Director | 1.4yrs | US$176.42k | no data | |
| Director | less than a year | no data | no data |
17.3yrs
Average Tenure
65yo
Average Age
Experienced Board: LXRX's board of directors are seasoned and experienced ( 17.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:18 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lexicon Pharmaceuticals, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Kevin Kedra | G. Research, LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |